Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study
Top Cited Papers
- 1 November 2001
- journal article
- clinical trial
- Published by American Academy of Pediatrics (AAP)
- Vol. 108 (5), e83
- https://doi.org/10.1542/peds.108.5.e83
Abstract
Objective. Atomoxetine is an investigational, nonstimulant pharmacotherapy being studied as potential treatment for attention-deficit/hyperactivity disorder (ADHD). It is thought to act via blockade of the presynaptic norepinephrine transporter in the brain. We assessed the efficacy of 3 doses of atomoxetine compared with placebo in children and adolescents with ADHD. Methods. A total of 297 children and adolescents who were 8 to 18 years of age and had ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, were randomized to placebo or atomoxetine dosed on a weight-adjusted basis at 0.5 mg/kg/day, 1.2 mg/kg/day, or 1.8 mg/kg/day for an 8-week period. ADHD symptoms, affective symptoms, and social and family functioning were assessed using parent and investigator rating scales. Results. Approximately 71% of children enrolled were male, approximately 67% met criteria for mixed subtype (both inattentive and hyperactive/impulsive symptoms), and the only common psychiatric comorbidity was oppositional defiant disorder (approximately 38% of the sample). At baseline, symptom severity was rated as moderate to severe for most children. At endpoint, atomoxetine 1.2 mg/kg/day and 1.8 mg/kg/day were consistently associated with superior outcomes in ADHD symptoms compared with placebo and were not different from each other. The dose of 0.5 mg/kg/day was associated with intermediate efficacy between placebo and the 2 higher doses, suggesting a graded dose-response. Social and family functioning also were improved in the atomoxetine groups compared with placebo with statistically significant improvements in measures of children's ability to meet psychosocial role expectations and parental impact. Discontinuations as a result of adverse events were Conclusion. Among children and adolescents aged 8 to 18, atomoxetine was superior to placebo in reducing ADHD symptoms and in improving social and family functioning symptoms. Atomoxetine was associated with a graded dose-response, and 1.2 mg/kg/day seems to be as effective as 1.8 mg/kg/day and is likely to be the appropriate initial target dose for most patients. Treatment with atomoxetine was safe and well tolerated.Keywords
This publication has 17 references indexed in Scilit:
- Impairment and Deportment Responses to Different Methylphenidate Doses in Children With ADHD: The MTA Titration TrialJournal of the American Academy of Child & Adolescent Psychiatry, 2001
- Clinical Practice Guideline: Diagnosis and Evaluation of the Child With Attention-Deficit/Hyperactivity DisorderPediatrics, 2000
- A 14-Month Randomized Clinical Trial of Treatment Strategies for Attention-Deficit/Hyperactivity DisorderArchives of General Psychiatry, 1999
- Practice Parameters for the Assessment and Treatment of Children, Adolescents, and Adults With Attention-Deficit/Hyperactivity DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 1997
- A Naturalistic Assessment of Protriptyline for Attention-Deficit Hyperactivity DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 1996
- Nortriptyline in the Treatment of ADHD: A Chart Review of 58 CasesJournal of the American Academy of Child & Adolescent Psychiatry, 1993
- A Retrospective Study of Serum Levels and Electrocardiographic Effects of Nortriptyline in Children and AdolescentsJournal of the American Academy of Child & Adolescent Psychiatry, 1993
- Nortriptyline Treatment of Children with Attention-deficit Hyperactivity Disorder and Tic Disorder or Tourette's SyndromeJournal of the American Academy of Child & Adolescent Psychiatry, 1993
- Hyperactivity at Adolescence: Some Misconceptions and New DirectionsJournal of Clinical Child Psychology, 1986
- Review of follow-up and follow-back studies of childhood hyperactivity.Psychological Bulletin, 1984